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Sodium channels and nociception – the effects
of local anesthetics
Abstract
Background and Purpose: Pain is an unpleasant warning sensation of
imminent damage of the tissue or organ, and is a very frequent reason for
patients to seek the physician's help. The aim of this paper is to give an over-
view on the role of voltage gated sodium channels in nociception and to
highlight the mechanisms of the action of local anesthetics in inhibiting
conduction of ion currents, thus affecting the sense of pain.
Materials and Methods: A comprehensive search of the literature with
key words: voltage gated sodium channels (VGSC), nociception, local anes-
thetics, a, b- subunit isoforms in Medline was conducted.
Results: VGSC isoforms Nav1.7, Nav1.8, Nav1.9 are highly expressed in
nociceptive neurons and associated with neuropathic pain syndrome. Hu-
man studies demonstrated that point mutations of these isoforms, particu-
larly Nav1.7 underlie insensitivity or hypersensitivity to pain. The sodium
channel blockers are anesthetics of choice for local analgesia and anesthesia.
However, currently available drugs are not considered selective enough and
have relatively narrow therapeutic windows, which can limit their useful-
ness. Isoform – selective pharmacological blockers or gene therapy ap-
proaches targeted at down-regulating specific isoforms could show in-
creased therapeutic efficacy for treating pain.
Conclusions: Due to restrictive appearance of isoforms Nav1.7 and
Nav1.8 in nociceptive neurons, drugs targeting these isoforms would be of
great interest, especially in treatment of neuropathic pain syndrome.
Pain is an unpleasant warning sensation of imminent damage of thetissue or organ, and is a very frequent reason for patients seeking
the physician's help.
Peripheral neurons – nociceptors relay information about noxious
stimuli in the periphery to the central nervous system. Activation of
both central and peripheral neurons contributes to increased sense of
pain. Nociception and altered pain sensitivity occurs due to changing of
the activity of ion channels, mainly voltage-gated sodium channels (1).
These channels are crucial in clinically relevant analgesics, such as
lidocaine (1).
Sodium channels are composed of a-subunit, the primary func-
tional unit of voltage-gated sodium channel, which could be associated
with four different b-subunits (b1, b2, b3 and b4)–(2,3). It is likely that
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Overview
brane and/or localization of the a-subunits to specific
membrane domains (3). In addition several other acces-
sory proteins such as calmodulin (4) or annexin II (5)
that have been identified may be important modulators
of voltage-gated sodium channels.
Nine distinct voltage-gated sodium channel a-sub-
units (Nav1.1-1.9) have been cloned from mammals (6).
The predominant sodium channel isoforms in nocicep-
tive neurons are Nav1.7, Nav1.8, and Nav1.9. (7). Addi-
tionally, Nav1.1, Nav1.3, and Nav1.6, are the very impor-
tant voltage-gated sodium channels expressed in
peripheral sensory neurons (1). The role of Nav1.3
channels in pain is controversial. Nav1.3 is expressed in
developing neurons, and down-regulated in mature neu-
rons (8), but are re-expressed in a condition of neuropathic
pain and inflammation (9), contributing to the overall
sodium current and the neuronal hyperexcitability ob-
served in dorsal root ganglion (DRG) sensory neurons
following nerve injury or inflammation. Nav1.6 is the
predominant voltage-gated sodium channel located in
the nodes of Ranvier in both peripheral and central ner-
vous system myelinated neurons (10), The role of Nav1.6,
if any, in nociception and pain sensations is not clear.
Similarly, Nav1.1, although it is expressed in central and
peripheral neurons, has no clear place in nociception.
Several recent studies have demonstrated that com-
plete loss of function of one specific voltage gated sodium
channel, which expresses Nav1.7 isoform, results in com-
plete insensitivity to pain (11, 12). On the other hand,
subtle, but significant changes in gating properties of so-
dium channels caused by point mutations of Nav1.7, can
result in increased pain sensations and contribute to the
development of chronic pain syndrome, such as the fa-
miliar painful inherited neuropathy, inherited erythro-
melalgia (13, 14). At least 9 distinct point mutations in
SCN9A altering the amino acid sequence of Nav1.7
channels (13, 14). Mutations in the Nav1.7 channels are
identified cause significant hyperpolarizing shifts in the
channel V1/2 of activation as well as larger ramp currents
(13, 15). Other Nav1.7 point mutations underlie a sec-
ond autosomal dominant chronic pain disorder, paroxys-
mal extreme pain disorder (PEPD), characterized by severe
burning rectal, ocular and submandibular pain sensation
(16).
Another isoform of voltage-gated sodium channels,
Nav1.8, is almost exclusively expressed in nociceptive
neurons, and is important in normal pain function. Nav1.8
is a tetrodotoxin resistant (TTX-R) sodium channel and
is highly expressed in small-diameter sensory neurons.
Nav1.8 plays a role in inflammatory pain and the onset
of neuropathic pain (1). Nav1.8 also plays a role in hy-
perexcitability in inherited erythromelalgia, together with
Nav1.7 isoform (1). More than 50% of C fibers and 10%
of A fibers express Nav1.8 channels. The expression and
biophysical properties of Nav1.8 channels can be modu-
lated by ongoing nociceptive input (17). Because of the
exclusive expression of Nav1.8, a selective Nav1.8 chan-
nel inhibitor would be useful in treating inflammatory
pain and should be able to provide solid data on the role
of Nav1.8 in human neuropathic pain (CUMMINS 2007).
Studies on transgenic mice indicate the Nav1.9 channel,
along with Nav1.7 and Nav1.8, may be an important
contributor to inflammatory pain, but may not be crucial
to neuropathic pain associated with nerve injury (17,
18). The modulation of a tetrodotoxin (TTX) – resistant
voltage-gated sodium current (such as via Nav1.8) may
underlie inflammation-induced sensitization of nocicep-
tion of high-threshold primary afferent neurons (19).
Modulation of TTX-R currents is an endogenous mech-
anism used to control neuronal excitability, and therapeu-
tic intervention blocking that current could be effective
in treatment of hyperalgesia and pain (19). For example, a
study by Gold et al. showed that u-opioid receptor ago-
nist blocked PGE2-induced modulation of the current.
Furthermore, because of the restricted distribution of
TTX-R Na1 currents and the observation that a decrease
in the expression of these currents has little impact on
low threshold mechanical transduction, targeting these
currents may lead to the development of a pharmaco-
therapy for the treatment of hyperalgesia with fewer side
effects than currently available drugs (19).
Several different types of sodium channel isoforms are
preferentially expressed in the peripheral sensory neu-
rons, and some of them can be regulated by inflamma-
tion or axonal injury (1). For example, Nav1.7 are up-
regulated in chronic inflammation (20, 21), suggesting
their role in increased pain sensations associated with in-
flammation. It is known that calmodulin (CaM) can
modulate Nav1.4 (skeletal muscle) and Nav1.6 (neuro-
nal) current amplitudes and properties (4). However, a
(new) recent study demonstrated that inhibition of so-
dium current caused by the CaM inhibitor trifloupera-
zine (TFP) is largely independent of the inhibition of
CaM interaction with Nav subunit of voltage gated so-
dium channels, but can be attributed to direct interaction
of the drug with the sodium channels in a state-depend-
ent manner. The ability of TFP to block Nav1.7 at low
doses could make it a potential therapeutic regimen for
regional anesthesia and pain management that would be
more potent than traditional local anesthetics (7).
The almost exclusive expression patterns of the volt-
age – gated sodium channels that are associated with
pain makes them very attractive targets for the develop-
ment of novel analgesics. Sodium channels are subject to
extensive modulation in various pathophysiological con-
ditions, such as inflammation or nerve injury as well as
pharmacologically induced by drugs. For example, te-
trodotoxin (TTX) can block these channels with a high
degree of selectivity. TTX and other toxins were invalu-
able tools in uncovering the functional properties of so-
dium channels and their roles in electro-excitability. Other
substances that interact with sodium channels, such as
local anesthetics (LA), class I antiarrhythmic drugs and
anticonvulsants, are now commonly used to treat pain,
epilepsy, ataxias and other pathophysiological conditions
(22, 23). LAs are very effective in preventing the sense of
nociception, by blocking sodium currents through volt-
age-gated sodium channels, thus inhibiting the conduc-
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tion of action potentials in excitable tissues, specifically
neural tissues. The most commonly used drugs are:
bupivacaine, levobupivacaine, ropivacaine and lidocaine
(24). Binding of LAs to inactivated Na+-channels at the
binding sites inside sodium channels (25), inactivates it
and prevents the influx of sodium intracellularly. In this
way the spreading of a depolarization wave throughout
the cell membrane is suppressed (26). LAs are known to
produce hyperpolarizing shifts in steady-state inactiva-
tion and use-dependent inhibition of sodium currents by
binding to a receptor site on the ion channel (27, 28).
It is interesting to note that several phenothiazine
neuroleptics structurally related to TFP can also block-
sodium currents in a use-dependent manner (29, 31).
These studies and a study by Sheets et al. (7) demonstrat-
ing that TFP causes hyperpolarizing shifts in steady-state
inactivation, exhibiting a higher apparent affinity for in-
activated channels and exhibiting a concentration inde-
pendent recovery from inhibition indicates that TFP
might interact directly with Nav1.7 and Nav1.4 through
the LA binding site. Observation that the nerve block by
TFP is more potent than lidocaine (7) suggests that TFP
or TFP analogues might be useful for inducing pro-
longed nerve block.
Apart from the treatment of neuropathic pain, LAs
are clearly useful in many clinical situations for the treat-
ment of pain. Typical LAs (such as lidocaine and carba-
mazepine) inhibit voltage-gated sodium currents, pro-
ducing both tonic and phasic (use-dependent) block of
sodium currents that often involves negative shifts in the
voltage-dependence of steady-state inactivation, indica-
tive of enhanced binding to inactivated channels. Al-
though these drugs are very useful clinically, they do not
always show high specificity for sodium channels over
other types of ion channels, and in general there are only
subtle differences in their effects on the different sodium
channel isoforms. Recent studies on peripheral neuronal
isoforms indicate Nav1.8 may differ in its sensitivity to
some of these compounds. Cardenas et al. (32) reported
that the interaction between carbamazepine and Nav1.8-
-like currents in DRG neurons was slower than the inter-
action between TTX-sensitive channels and carbamaze-
pine. Interestingly, it has been proposed that the novel
small molecule inhibitor of Nav1.8, A-803467 (17) may
bind at a distinct site from the local anesthetic binding
site.
Although anesthetics of choice for local analgesia and
anesthesia, the sodium channel blockers currently avail-
able are not considered sufficiently selective and have rela-
tively narrow therapeutic windows, which can limit their
usefulness. Isoform – selective pharmacological blockers
or gene therapy approaches targeted at down-regulating
specific isoforms could show increased therapeutic effi-
cacy for treating pain. In treatment of human neuropathic
pain syndrome, drugs targeting Nav1.7 and Nav1.8 would
be of the greatest interest, due to the restrictive appear-
ance of these isoforms in nociceptive neurons.
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